SCHEMBL4385896

SCHEMBL4385896

CCCCCCNCCCC[C@H](N)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.57
GRIK2 Q13002 2/20 0.57
GNAI3 P08754 1/20 0.55
GNAO1 P09471 1/20 0.55
GNAI1 P63096 1/20 0.55
NOD1 Q9Y239 5/20 0.55
DPP7 Q9UHL4 2/20 0.54
SLC1A2 P43004 2/20 0.54
SLC1A1 P43005 2/20 0.54
GSR P00390 1/20 0.50
RRM1 P23921 1/20 0.50
GPR84 Q9NQS5 3/20 0.48
FFAR1 O14842 1/20 0.48
DDAH1 O94760 1/20 0.47
ANPEP P15144 1/20 0.47
ERAP2 Q6P179 1/20 0.47
NOS2 P35228 1/20 0.47
SLC1A3 P43003 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10615527 1.00 GRIK1 (0.57) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL27608418 0.98 GRIK1 (0.56) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL28032333 0.98 GRIK1 (0.56) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL9362560 0.98 GRIK1 (0.56) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL460141 0.98 GRIK1 (0.56) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL25635471 0.96 NOD1 (0.55) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL10285774 0.95 NOD1 (0.52) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL10286387 0.95 NOD1 (0.52) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL22777682 0.93 GRIK1 (0.53) GRIK1GRIK2GNAI3GNAO1GNAI1
SCHEMBL25227671 0.91 GSR (0.52) GRIK1GRIK2GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3467106-B1 PEPTIDE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2025-07-09 EP disclosed
US-10087229-B2 Peptide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-02 US disclosed
US-20160052988-A1 PEPTIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 US disclosed
US-9200051-B2 Peptide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-01 US disclosed
US-20140357552-A1 PEPTIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-04 US disclosed
EP-1748805-B1 ABSORBABLE BIOCOMPATIBLE COATINGS BIOINTERACTIONS LTD (GB) 2009-07-29 EP disclosed
CN-1956742-A Absorbable biocompatible materials BIOINTERACTIONS LTD (GB) 2007-05-02 CN disclosed
EP-1748805-A1 ABSORBABLE BIOCOMPATIBLE MATERIALS Biointeractions Ltd. (GB) 2007-02-07 EP disclosed
US-20060134166-A1 Absorbable biocompatible materials BIOINTERACTIONS LTD. (GB) 2006-06-22 US disclosed
WO-2005115492-A1 ABSORBABLE BIOCOMPATIBLE MATERIALS BIOINTERACTIONS LTD (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052988-A1 PEPTIDE COMPOUND GIPR, GLP1R, VIP GRIK1 1026/4885GRIK2 2186/4885GNAI3 590/4885
US-20060134166-A1 Absorbable biocompatible materials ADM2, HDGF, SLC7A1 GRIK1 3278/4885GRIK2 3220/4885GNAI3 3841/4885
US-20140357552-A1 PEPTIDE COMPOUND GLP1R, GIPR, VIP GRIK1 795/4885GRIK2 1793/4885GNAI3 459/4885
US-10087229-B2 Peptide compound GLP1R, GIPR, VIP GRIK1 953/4885GRIK2 1939/4885GNAI3 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.